N@N

Insulet Corporation Announces Commencement of Public Offering of Shares of Common Stock

_{//health-fitness.news-articles.net/content/2009/ .. f-public-offering-of-shares-of-common-stock.html}
^{Published in Health and Fitness on Wednesday, October 28th 2009 at 13:10 GMT by Market Wire}  

BEDFORD, MA--(Marketwire - October 28, 2009) - Insulet Corporation (NASDAQ: [ PODD ]) today announced that it will initiate, subject to market conditions, an underwritten public offering of 5,500,000 shares of common stock under an effective shelf registration statement on file with the Securities and Exchange Commission. It is currently anticipated that the underwriters will be granted an over-allotment option to purchase up to an additional 825,000 shares of common stock.

J.P. Morgan Securities Inc. is acting as sole book-running manager of the offering. The company currently expects to use the net proceeds of this offering for general corporate purposes, which may include the repayment of certain outstanding debt obligations.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained by contacting Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; or by calling (681) 254-1735.

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Federal securities laws. These forward-looking statements are based on Insulet's current expectations and beliefs concerning future developments and their potential effects on it. There can be no assurance that future developments affecting it will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties described in the section entitled "Risk Factors" in Insulet's Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 16, 2009, and in the section entitled "Risk Factors" in Insulet's Quarterly Report on Form 10-Q, which was filed on October 26, 2009, and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.